P Touraine

Summary

Country: France

Publications

  1. ncbi Hormonal status in protracted critical illness and in-hospital mortality
    Tarek Sharshar
    Department of Intensive Care Medicine, AP HP, Raymond Poincare Hospital, University Versailles Saint Quentin en Yvelines, 104 Bd Raymond Poincaré, Garches F 92380, France
    Crit Care 15:R47. 2011
  2. ncbi Breast inflammatory gigantomastia in a context of immune-mediated diseases
    P Touraine
    Department of Endocrinology and Reproductive Medicine, Hopital Necker, 149, rue de Sevres, 75743 Paris Cedex 15, France
    J Clin Endocrinol Metab 90:5287-94. 2005
  3. ncbi [Management of families at high risk for hereditary breast-ovarian cancers: the endocrinologist's point of view]
    C Courtillot
    Service d endocrinologie et médecine de la reproduction, Groupe Hospitalier Pitie Salpetriere, 47 83, Boulevard de l Hopital, 75013 Paris, France
    Ann Endocrinol (Paris) 69:193-200. 2008
  4. ncbi [Phenotype-genotype correlation in mutations of the gonadotrophin receptor gene in women]
    P Touraine
    Departement d Endocrinologie et Medecine de la Reproduction, Assistance Publique Hopitaux de Paris, Groupe Hospitalier Pitie Salpetriere, 75651 Paris Cedex 13, France
    Ann Endocrinol (Paris) 71:203-5. 2010
  5. ncbi Evaluation of different markers of the ovarian reserve in patients presenting with premature ovarian failure
    N Massin
    Department of Endocrinology and Reproductive Medicine, GH Pitié Salpêtrière 47 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Mol Cell Endocrinol 282:95-100. 2008
  6. ncbi Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors
    Roman L Bogorad
    Institut National de la Santé et de la Recherche Médicale U845, Equipe PRL, GH et Tumeurs, Centre de Recherche Croissance et Signalisation, F 75015 Paris, France
    Proc Natl Acad Sci U S A 105:14533-8. 2008

Collaborators

  • C Duflos
  • C Balleyguier
  • J C Carel
  • B Eymard
  • A May
  • C Courtillot
  • E Thibaud
  • Anne Gompel
  • Genevieve Plu-Bureau
  • Brigitte Sigal-Zafrani
  • Vincent Goffin
  • Tarek Sharshar
  • A Bachelot
  • N Massin
  • Roman L Bogorad
  • F Kuttenn
  • Herve Outin
  • Andrea Polito
  • Pablo Rodriguez
  • Virginie Maxime
  • Kathleen Laborde
  • Charles Cerf
  • Bernard De Jonghe
  • Sylvie Bastuji-Garin
  • Robert D Stevens
  • B Raccah Tebbeca
  • J Caby
  • Paul A Kelly
  • J Bensimhon
  • H Charitanski
  • A Perrin
  • H Hofman
  • S Yacoub
  • O Fiori
  • C Hofman
  • Sophie Bernichtein
  • B Brethon
  • G Delattre
  • J Berdah
  • A Boudinet
  • B Sigal Zafrani
  • M A Le Frere-Belda
  • A Thoury
  • C Nos
  • Frederique Kuttenn
  • Lilya Harutyunyan
  • R Salmon
  • Chidi Mestayer
  • K Clough
  • B Belaroussi
  • Jean Baptiste Jomain
  • N Chabbert Buffet
  • C Gracia
  • C Bricaire
  • I Denys
  • J C Thalabard
  • K B Triana Rabi
  • F Laki
  • G Caillaud
  • G Gibaud
  • M Detoeuf
  • F Martinez
  • M A Le Frere Belda
  • L Meng
  • S Uzan
  • K B Triana-Rabi
  • J P Lefranc
  • D Pelletier
  • B Raccah-Tebbeca
  • D Leger
  • G Plu Bureau
  • J Viriot
  • J C Saiovici
  • C Dhainault
  • G Meduri
  • K Desthieux Ngo
  • Jean-Baptiste Jomain
  • A Grimard
  • K Desthieux-Ngo
  • M J Blin
  • M Misrahi
  • C Chretien
  • M Sibout
  • C Lanty
  • N Chabbert-Buffet
  • C Genestie
  • Anne Bachelot

Detail Information

Publications6

  1. ncbi Hormonal status in protracted critical illness and in-hospital mortality
    Tarek Sharshar
    Department of Intensive Care Medicine, AP HP, Raymond Poincare Hospital, University Versailles Saint Quentin en Yvelines, 104 Bd Raymond Poincaré, Garches F 92380, France
    Crit Care 15:R47. 2011
    ..The aim of this study was to determine the relationship between hormonal status and mortality in patients with protracted critical illness...
  2. ncbi Breast inflammatory gigantomastia in a context of immune-mediated diseases
    P Touraine
    Department of Endocrinology and Reproductive Medicine, Hopital Necker, 149, rue de Sevres, 75743 Paris Cedex 15, France
    J Clin Endocrinol Metab 90:5287-94. 2005
    ..Localized breast lesions have been described in lupic or diabetic patients. However, the description of breast gigantomastia in women presenting with autoimmune diseases has not been reported...
  3. ncbi [Management of families at high risk for hereditary breast-ovarian cancers: the endocrinologist's point of view]
    C Courtillot
    Service d endocrinologie et médecine de la reproduction, Groupe Hospitalier Pitie Salpetriere, 47 83, Boulevard de l Hopital, 75013 Paris, France
    Ann Endocrinol (Paris) 69:193-200. 2008
    ..It is best that counseling be given in an interdisciplinary cancer genetic clinic, where all practionners are aware of the latest data and guidelines...
  4. ncbi [Phenotype-genotype correlation in mutations of the gonadotrophin receptor gene in women]
    P Touraine
    Departement d Endocrinologie et Medecine de la Reproduction, Assistance Publique Hopitaux de Paris, Groupe Hospitalier Pitie Salpetriere, 75651 Paris Cedex 13, France
    Ann Endocrinol (Paris) 71:203-5. 2010
    ..The discovery of these mutations allows a better understanding of some genotypes and is helpful in advancing our knowledge of these receptors...
  5. ncbi Evaluation of different markers of the ovarian reserve in patients presenting with premature ovarian failure
    N Massin
    Department of Endocrinology and Reproductive Medicine, GH Pitié Salpêtrière 47 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Mol Cell Endocrinol 282:95-100. 2008
    ..Finally, AMH levels in POF patients could identify women with persistent follicles...
  6. ncbi Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors
    Roman L Bogorad
    Institut National de la Santé et de la Recherche Médicale U845, Equipe PRL, GH et Tumeurs, Centre de Recherche Croissance et Signalisation, F 75015 Paris, France
    Proc Natl Acad Sci U S A 105:14533-8. 2008
    ..Hallmarks of constitutive activity were all reversed by a specific PrlR antagonist, which opens potential therapeutic approaches for MFA, or any other disease that could be associated with this mutation in future...